The previous study indicated that men treated with PD‐1 inhibitor had two‐times lower the risk of death than women.31 The result was partly in accordance with Grassadonia’s study (male: HR 0.67, 95% CI 0.55‐0.80; female: HR 0.77, 95% CI 0.57‐1.05) and Wu’s study (male: HR 0.60, 95% CI 0.36‐0.84; female: HR 0.88, 95% CI 0.68‐1.08), which revealed no significant improvement in PFS in women in NSCLC.32, 33 Therefore, it remains a controversy and under‐investigated issue whether magnitude of overall survival and progression‐free survival advantage from immunotherapy are sex‐dependent. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.